SELECTA BIOSCIENCES INC (29)
Browse by Contract Category
Contracts
-
Employment Agreement, dated July 31, 2020, by and between Selecta Biosciences, Inc. and Peter G. Traber, M.D
(Filed With SEC on November 5, 2020)
-
Registration Rights Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ), as amended on November 4, 2020
(Filed With SEC on November 5, 2020)
-
Letter agreement, dated August 31, 2020, among Selecta Biosciences, Inc., Oxford Finance LLC and Silicon Valley Bank
(Filed With SEC on September 3, 2020)
-
License and Development Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)
(Filed With SEC on August 6, 2020)
-
Lease Agreement by and between BRE-BMR Grove LLC and Selecta Biosciences, Inc. dated July 23, 2019
(Filed With SEC on November 8, 2019)
-
Loan and Security Agreement, dated August 31, 2020, between Selecta Biosciences, Inc., Oxford Finance LLC, as Collateral Agent and as a lender, and Silicon Valley Bank, as a lender
(Filed With SEC on September 3, 2020)
-
Form of Warrant to Purchase Stock, dated August 31, 2020, issued by Selecta Biosciences, Inc. to Oxford Finance LLC and Silicon Valley Bank, together with a schedule of warrants
(Filed With SEC on September 3, 2020)
-
Open Market Sale Agreement, dated as of August 6, 2020, by and between Selecta Biosciences, Inc. and Jefferies LLC
(Filed With SEC on August 6, 2020)
-
Stock Purchase Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)
(Filed With SEC on August 6, 2020)
-
Registration Rights Agreement, dated as of June 11, 2020, by and between the Registrant and Swedish Orphan Biovitrum AB (Publ)
(Filed With SEC on August 6, 2020)
-
Fifth Amendment to Exclusive Patent License Agreement, dated as of May 15, 2020, by and between the Registrant and the Massachusetts Institute of Technology
(Filed With SEC on August 6, 2020)
-
Transition Agreement and Release, dated June 25, 2020, between Selecta Biosciences, Inc. and Elona Kogan
(Filed With SEC on June 25, 2020)
-
Transition Agreement and Release, dated June 25, 2020, between Selecta Biosciences, Inc. and Stephen Smolinski
(Filed With SEC on June 25, 2020)
-
Non-Employee Director Compensation Program
(Filed With SEC on May 7, 2020)
-
Fourth Amendment to Exclusive Patent License Agreement, entered into on December 13, 2019, by and between the Massachusetts Institute of Technology and the Registrant
(Filed With SEC on March 12, 2020)
-
Description of Securities
(Filed With SEC on March 12, 2020)
-
Securities Purchase Agreement, dated December 18, 2019, by and among Selecta Biosciences, Inc. and the Investors named therein
(Filed With SEC on December 26, 2019)
-
Registration Rights Agreement, dated December 23, 2019, by and among Selecta Biosciences, Inc. and the Investors named therein
(Filed With SEC on December 26, 2019)
-
Form of Common Stock Purchase Warrant, dated December 23, 2019
(Filed With SEC on December 26, 2019)
-
Form of Pre-Funded Common Stock Purchase Warrant, dated December 23, 2019
(Filed With SEC on December 26, 2019)
-
Feasibility Study and License Agreement by and between Asklepios BioPharmaceutical, Inc. and Selecta Biosciences, Inc. dated August 6, 2019
(Filed With SEC on November 8, 2019)
-
Employment Agreement, dated August 12, 2019, by and between Selecta Biosciences, Inc. and Bradford D. Dahms
(Filed With SEC on November 8, 2019)
-
Stock Purchase Agreement, dated August 19, 2019, by and among Selecta Biosciences, Inc. and the Investors named therein
(Filed With SEC on August 20, 2019)
-
Employment Agreement, dated June 21, 2019, by and between Selecta Biosciences, Inc. and Alison Schecter, M.D
(Filed With SEC on August 8, 2019)
-
Employment Offer Letter, dated July 29, 2016, between Selecta Biosciences, Inc. and Ann K. Donohue, and Promotion Letter dated November 30, 2017
(Filed With SEC on May 9, 2019)
-
Employment Agreement, dated March 19, 2019, between Selecta Biosciences, Inc. and Elona Kogan
(Filed With SEC on May 9, 2019)
-
Amendment to Consulting Agreement, dated December 31, 2018, to Consulting Agreement by and between Registrant and Omid Farokzhad, dated May 30, 2018
(Filed With SEC on March 15, 2019)
-
Transition Agreement and Release, dated March 6, 2019, between Selecta Biosciences, Inc. and John Leaman, M.D
(Filed With SEC on March 8, 2019)
-
Underwriting Agreement, dated January 23, 2019, between the Company and Stifel, Nicolaus & Company, Incorporated, as representative of the several underwriters named therein
(Filed With SEC on January 24, 2019)